Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


When Will Gilead Make Its M&A Move?

Executive Summary

While HCV sales continue to slow due to a lengthy list of factors, Gilead is seeing a strong launch for revised HIV combo therapies incorporating TAF – but most analysts believe that major M&A is needed to offset stagnation.


Related Content

Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Gilead Plays Up Its Strength As Market Awaits Business Development Moves
Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild
Gilead: Three HIV Launches Expected In Near-Term Future


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts